ATE239729T1 - 2,3-benzodiazepin-derivate - Google Patents

2,3-benzodiazepin-derivate

Info

Publication number
ATE239729T1
ATE239729T1 AT98936578T AT98936578T ATE239729T1 AT E239729 T1 ATE239729 T1 AT E239729T1 AT 98936578 T AT98936578 T AT 98936578T AT 98936578 T AT98936578 T AT 98936578T AT E239729 T1 ATE239729 T1 AT E239729T1
Authority
AT
Austria
Prior art keywords
benzodiazepine derivatives
benzodiazepines
epilepsy
stereoisomers
variables
Prior art date
Application number
AT98936578T
Other languages
English (en)
Inventor
Gizella Abraham
Emese Csuzdi
Sandor Solyom
Pal Berzsenyi
Istvan Tarnawa
Ferenc Andrasi
Istvan Ling
Tamas Hamori
Katalin Horvath
Imre Moravcsik
Istvan Pallagi
Antal Simay
Original Assignee
Gyogyszerkutato Intezet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gyogyszerkutato Intezet filed Critical Gyogyszerkutato Intezet
Application granted granted Critical
Publication of ATE239729T1 publication Critical patent/ATE239729T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98936578T 1997-07-31 1998-07-27 2,3-benzodiazepin-derivate ATE239729T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701325A HUP9701325A1 (hu) 1997-07-31 1997-07-31 Új 2,3-benzodiazepin-származékok
PCT/HU1998/000071 WO1999006408A1 (en) 1997-07-31 1998-07-27 New 2,3-benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
ATE239729T1 true ATE239729T1 (de) 2003-05-15

Family

ID=89995445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936578T ATE239729T1 (de) 1997-07-31 1998-07-27 2,3-benzodiazepin-derivate

Country Status (13)

Country Link
US (1) US6482819B1 (de)
EP (1) EP1001956B1 (de)
JP (1) JP2001512124A (de)
KR (2) KR100521959B1 (de)
AT (1) ATE239729T1 (de)
AU (1) AU741162B2 (de)
CA (1) CA2296586C (de)
DE (1) DE69814401T2 (de)
DK (1) DK1001956T3 (de)
ES (1) ES2202879T3 (de)
HU (1) HUP9701325A1 (de)
PT (1) PT1001956E (de)
WO (1) WO1999006408A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041671C1 (de) * 2000-08-10 2002-06-13 Schering Ag Verfahren zur Herstellung von Imidazo[1,2-c][2,3]benzodiazepinen sowie Phenylessigsäureester und Oxazol-Derivate als Zwischenprodukte bei deren Herstellung
EP2338492A1 (de) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
CN112321401B (zh) * 2020-11-10 2023-04-28 西安石油大学 一种催化氧化异色满制备2-羟乙基苯基酮的方法
JPWO2023042887A1 (de) 2021-09-15 2023-03-23
JPWO2023042888A1 (de) 2021-09-15 2023-03-23

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
DE4428835A1 (de) 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
WO1996006606A1 (en) 1994-08-31 1996-03-07 Eli Lilly And Company Dihydro-2,3-benzodiazepine derivatives
DE19604919A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AU741162B2 (en) 2001-11-22
EP1001956A1 (de) 2000-05-24
KR20010022287A (ko) 2001-03-15
WO1999006408A1 (en) 1999-02-11
PT1001956E (pt) 2003-09-30
DE69814401D1 (de) 2003-06-12
AU8554098A (en) 1999-02-22
KR100521959B1 (ko) 2005-10-14
CA2296586C (en) 2007-04-03
DE69814401T2 (de) 2004-02-26
CA2296586A1 (en) 1999-02-11
DK1001956T3 (da) 2003-08-18
KR20010022294A (ko) 2001-03-15
HU9701325D0 (en) 1997-09-29
US6482819B1 (en) 2002-11-19
HUP9701325A1 (hu) 2000-08-28
EP1001956B1 (de) 2003-05-07
JP2001512124A (ja) 2001-08-21
ES2202879T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
MY133392A (en) Novel substituted pyrazole derivatives
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
DE69716810T2 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
DK1056704T3 (da) Antitumormidler
BG104983A (en) Aryl fused azapolycyclic compounds
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
DK1001956T3 (da) 2,3-Benzodiazepinderivater
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69822937D1 (de) Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
GEP19991780B (en) Use of Pyrrolidine Derivatives for Treating Alcoholism
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
ATE204294T1 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
DE60313005D1 (de) Behandlung von dyskinesie mit 2,3-benzodiazepinen
ATE158792T1 (de) 2, 3-dihydro-4(1h)-quinazolinone zu magen- darmtherapien
DE69614838T2 (de) Verfahren zur herstellung von anhydroecgonin-estern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001956

Country of ref document: EP

REN Ceased due to non-payment of the annual fee